Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $110.14, for a total value of $250,458.36.

Blueprint Medicines Stock Down 2.5 %

Shares of NASDAQ:BPMC opened at $90.72 on Thursday. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90. The stock has a market cap of $5.80 billion, a P/E ratio of -84.00 and a beta of 0.58. The business has a fifty day moving average of $98.84 and a two-hundred day moving average of $93.95. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on BPMC. Piper Sandler lifted their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Morgan Stanley started coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $128.00 target price on shares of Blueprint Medicines in a research note on Friday, February 28th. Jefferies Financial Group started coverage on Blueprint Medicines in a research note on Monday, March 17th. They issued a “buy” rating and a $135.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $124.95.

Institutional Trading of Blueprint Medicines

Institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in Blueprint Medicines during the third quarter worth $32,000. R Squared Ltd purchased a new position in shares of Blueprint Medicines during the 4th quarter worth $51,000. Headlands Technologies LLC acquired a new stake in shares of Blueprint Medicines during the 4th quarter worth about $65,000. Thematics Asset Management purchased a new stake in Blueprint Medicines in the 4th quarter valued at about $72,000. Finally, Covestor Ltd lifted its position in Blueprint Medicines by 62.7% in the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 375 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.